{"id":35647,"date":"2015-05-05T08:49:50","date_gmt":"2015-05-05T12:49:50","guid":{"rendered":"https:\/\/cablemanpro.com\/wallstreetpr\/?p=35647"},"modified":"2015-05-05T08:49:50","modified_gmt":"2015-05-05T12:49:50","slug":"isis-pharmaceuticals-inc-nasdaqisis-looks-forward-to-licensing-anti-clotting-drug-to-bayer","status":"publish","type":"post","link":"https:\/\/cablemanpro.com\/wallstreetpr\/isis-pharmaceuticals-inc-nasdaqisis-looks-forward-to-licensing-anti-clotting-drug-to-bayer-35647","title":{"rendered":"ISIS Pharmaceuticals, Inc. (NASDAQ:ISIS) Looks Forward To Licensing Anti-Clotting Drug To Bayer"},"content":{"rendered":"<p style=\"text-align: justify;\">The leading pharmaceutical company <strong>ISIS Pharmaceuticals, Inc. (NASDAQ:ISIS)<\/strong> plans to expand its business reach and market share. As per the <a href=\"http:\/\/www.marketwatch.com\/story\/isis-pharma-to-license-anticlotting-drug-to-bayer-2015-05-04\">reports<\/a>, the company has decided to license the anti-clotting drug to a Bayer AG unit. The initial payment received by ISIS Pharmaceuticals for this drug is as much as $100 million.<\/p>\n<p style=\"text-align: justify;\"><strong>What&#8217;s Next: <\/strong><\/p>\n<p style=\"text-align: justify;\">ISIS Pharmaceuticals&#8217; new anti-clotting drug is an experimental drug and has the potential to perform better in the future. As per the reports, as soon as the formalities of this deal get over, the Bayer HealthCare will start focusing on developing and commercializing this drug in the future.<\/p>\n<p style=\"text-align: justify;\">Bayer has bigger plans for this drug called ISIS-FXI. The company looks forward to evaluating it for all those patients who cannot use anticoagulants or the patients that have a huge risk of bleeding. Bayer has been trying hard to focus on thrombosis treatments over these years, and the current deal seems to take it closer to its focal point. As per the reports, it states that the anti-clotting drug named ISIS-FXI fulfills its expectations concerning the pipeline of thrombosis treatments. This is the primary reason Bayer decided to grab this opportunity as soon as it popped up.<\/p>\n<p style=\"text-align: justify;\">Thrombosis is a complex procedure that involves the complete information about blood-clotting that sometimes results in strokes and heart attacks. Reports claim that Isis Pharmaceuticals is entitled to receive $55 million payment after the execution of phase 2 study in those patients who are suffering from compromised kidney function. As per the terms of the deal, it is also eligible for various royalties and milestone payments from time to time.<\/p>\n<p style=\"text-align: justify;\">No one from the management of ISIS came forward to speak about this deal, which is expected to create value for all the shareholders in the coming months. Bayer is delighted to crack this offer and hopes that it will live up the expectations of all the stakeholders.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>The leading pharmaceutical company ISIS Pharmaceuticals, Inc. (NASDAQ:ISIS) plans to expand its business reach and market share. As per the reports, the company has decided [&hellip;]<\/p>\n","protected":false},"author":2,"featured_media":32293,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"rop_custom_images_group":[],"rop_custom_messages_group":[],"rop_publish_now":"initial","rop_publish_now_accounts":{"twitter_2902945987_2902945987":""},"rop_publish_now_history":[],"rop_publish_now_status":"pending","footnotes":""},"categories":[264],"tags":[4868,4869],"stock_ticker":[],"class_list":["post-35647","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-health","tag-isis-pharmaceuticals-inc-nasdaqisis","tag-nasdaqisis","entry"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v26.9 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>ISIS Pharmaceuticals, Inc. (NASDAQ:ISIS) Looks Forward To Licensing Anti-Clotting Drug To Bayer - Wall Street PR<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/cablemanpro.com\/wallstreetpr\/isis-pharmaceuticals-inc-nasdaqisis-looks-forward-to-licensing-anti-clotting-drug-to-bayer-35647\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"ISIS Pharmaceuticals, Inc. (NASDAQ:ISIS) Looks Forward To Licensing Anti-Clotting Drug To Bayer - Wall Street PR\" \/>\n<meta property=\"og:description\" content=\"The leading pharmaceutical company ISIS Pharmaceuticals, Inc. (NASDAQ:ISIS) plans to expand its business reach and market share. As per the reports, the company has decided [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/cablemanpro.com\/wallstreetpr\/isis-pharmaceuticals-inc-nasdaqisis-looks-forward-to-licensing-anti-clotting-drug-to-bayer-35647\" \/>\n<meta property=\"og:site_name\" content=\"Wall Street PR\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/WallStreetPR\/\" \/>\n<meta property=\"article:published_time\" content=\"2015-05-05T12:49:50+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/09\/Achillion-Pharmaceuticals-Inc.1.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"259\" \/>\n\t<meta property=\"og:image:height\" content=\"194\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Donna Fago\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Donna Fago\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/isis-pharmaceuticals-inc-nasdaqisis-looks-forward-to-licensing-anti-clotting-drug-to-bayer-35647#article\",\"isPartOf\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/isis-pharmaceuticals-inc-nasdaqisis-looks-forward-to-licensing-anti-clotting-drug-to-bayer-35647\"},\"author\":{\"name\":\"Donna Fago\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/60ece280249b1fa366ae54f87bb8ae84\"},\"headline\":\"ISIS Pharmaceuticals, Inc. (NASDAQ:ISIS) Looks Forward To Licensing Anti-Clotting Drug To Bayer\",\"datePublished\":\"2015-05-05T12:49:50+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/isis-pharmaceuticals-inc-nasdaqisis-looks-forward-to-licensing-anti-clotting-drug-to-bayer-35647\"},\"wordCount\":328,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#organization\"},\"image\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/isis-pharmaceuticals-inc-nasdaqisis-looks-forward-to-licensing-anti-clotting-drug-to-bayer-35647#primaryimage\"},\"thumbnailUrl\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/09\/Achillion-Pharmaceuticals-Inc.1.jpg\",\"keywords\":[\"ISIS Pharmaceuticals Inc. (NASDAQ:ISIS)\",\"NASDAQ:ISIS\"],\"articleSection\":[\"Health\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\/\/cablemanpro.com\/wallstreetpr\/isis-pharmaceuticals-inc-nasdaqisis-looks-forward-to-licensing-anti-clotting-drug-to-bayer-35647#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/isis-pharmaceuticals-inc-nasdaqisis-looks-forward-to-licensing-anti-clotting-drug-to-bayer-35647\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/isis-pharmaceuticals-inc-nasdaqisis-looks-forward-to-licensing-anti-clotting-drug-to-bayer-35647\",\"name\":\"ISIS Pharmaceuticals, Inc. (NASDAQ:ISIS) Looks Forward To Licensing Anti-Clotting Drug To Bayer - Wall Street PR\",\"isPartOf\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/isis-pharmaceuticals-inc-nasdaqisis-looks-forward-to-licensing-anti-clotting-drug-to-bayer-35647#primaryimage\"},\"image\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/isis-pharmaceuticals-inc-nasdaqisis-looks-forward-to-licensing-anti-clotting-drug-to-bayer-35647#primaryimage\"},\"thumbnailUrl\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/09\/Achillion-Pharmaceuticals-Inc.1.jpg\",\"datePublished\":\"2015-05-05T12:49:50+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/isis-pharmaceuticals-inc-nasdaqisis-looks-forward-to-licensing-anti-clotting-drug-to-bayer-35647#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/cablemanpro.com\/wallstreetpr\/isis-pharmaceuticals-inc-nasdaqisis-looks-forward-to-licensing-anti-clotting-drug-to-bayer-35647\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/isis-pharmaceuticals-inc-nasdaqisis-looks-forward-to-licensing-anti-clotting-drug-to-bayer-35647#primaryimage\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/09\/Achillion-Pharmaceuticals-Inc.1.jpg\",\"contentUrl\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/09\/Achillion-Pharmaceuticals-Inc.1.jpg\",\"width\":259,\"height\":194},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/isis-pharmaceuticals-inc-nasdaqisis-looks-forward-to-licensing-anti-clotting-drug-to-bayer-35647#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/cablemanpro.com\/wallstreetpr\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"ISIS Pharmaceuticals, Inc. (NASDAQ:ISIS) Looks Forward To Licensing Anti-Clotting Drug To Bayer\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#website\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/\",\"name\":\"Wall Street PR\",\"description\":\"Latest News From WallStreet\",\"publisher\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/cablemanpro.com\/wallstreetpr\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#organization\",\"name\":\"Wall Street PR\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2019\/10\/brand-logo.png\",\"contentUrl\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2019\/10\/brand-logo.png\",\"width\":537,\"height\":70,\"caption\":\"Wall Street PR\"},\"image\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/www.facebook.com\/WallStreetPR\/\",\"https:\/\/x.com\/WallstreetPRs\"]},{\"@type\":\"Person\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/60ece280249b1fa366ae54f87bb8ae84\",\"name\":\"Donna Fago\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2019\/06\/f15db860f556e28a86f628554c98485b.jpeg\",\"contentUrl\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2019\/06\/f15db860f556e28a86f628554c98485b.jpeg\",\"caption\":\"Donna Fago\"},\"description\":\"I believe in writing content Informing investors with the knowledge they need to invest better today- I have been following the markets for many years and was asked to join the team at WallStreetPR.com recently due to my passion for the markets.\",\"sameAs\":[\"http:\/\/www.WallStreetPR.com\"],\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/author\/darcie-fago\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"ISIS Pharmaceuticals, Inc. (NASDAQ:ISIS) Looks Forward To Licensing Anti-Clotting Drug To Bayer - Wall Street PR","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/cablemanpro.com\/wallstreetpr\/isis-pharmaceuticals-inc-nasdaqisis-looks-forward-to-licensing-anti-clotting-drug-to-bayer-35647","og_locale":"en_US","og_type":"article","og_title":"ISIS Pharmaceuticals, Inc. (NASDAQ:ISIS) Looks Forward To Licensing Anti-Clotting Drug To Bayer - Wall Street PR","og_description":"The leading pharmaceutical company ISIS Pharmaceuticals, Inc. (NASDAQ:ISIS) plans to expand its business reach and market share. As per the reports, the company has decided [&hellip;]","og_url":"https:\/\/cablemanpro.com\/wallstreetpr\/isis-pharmaceuticals-inc-nasdaqisis-looks-forward-to-licensing-anti-clotting-drug-to-bayer-35647","og_site_name":"Wall Street PR","article_publisher":"https:\/\/www.facebook.com\/WallStreetPR\/","article_published_time":"2015-05-05T12:49:50+00:00","og_image":[{"width":259,"height":194,"url":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/09\/Achillion-Pharmaceuticals-Inc.1.jpg","type":"image\/jpeg"}],"author":"Donna Fago","twitter_misc":{"Written by":"Donna Fago","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/isis-pharmaceuticals-inc-nasdaqisis-looks-forward-to-licensing-anti-clotting-drug-to-bayer-35647#article","isPartOf":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/isis-pharmaceuticals-inc-nasdaqisis-looks-forward-to-licensing-anti-clotting-drug-to-bayer-35647"},"author":{"name":"Donna Fago","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/60ece280249b1fa366ae54f87bb8ae84"},"headline":"ISIS Pharmaceuticals, Inc. (NASDAQ:ISIS) Looks Forward To Licensing Anti-Clotting Drug To Bayer","datePublished":"2015-05-05T12:49:50+00:00","mainEntityOfPage":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/isis-pharmaceuticals-inc-nasdaqisis-looks-forward-to-licensing-anti-clotting-drug-to-bayer-35647"},"wordCount":328,"commentCount":0,"publisher":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#organization"},"image":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/isis-pharmaceuticals-inc-nasdaqisis-looks-forward-to-licensing-anti-clotting-drug-to-bayer-35647#primaryimage"},"thumbnailUrl":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/09\/Achillion-Pharmaceuticals-Inc.1.jpg","keywords":["ISIS Pharmaceuticals Inc. (NASDAQ:ISIS)","NASDAQ:ISIS"],"articleSection":["Health"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/cablemanpro.com\/wallstreetpr\/isis-pharmaceuticals-inc-nasdaqisis-looks-forward-to-licensing-anti-clotting-drug-to-bayer-35647#respond"]}]},{"@type":"WebPage","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/isis-pharmaceuticals-inc-nasdaqisis-looks-forward-to-licensing-anti-clotting-drug-to-bayer-35647","url":"https:\/\/cablemanpro.com\/wallstreetpr\/isis-pharmaceuticals-inc-nasdaqisis-looks-forward-to-licensing-anti-clotting-drug-to-bayer-35647","name":"ISIS Pharmaceuticals, Inc. (NASDAQ:ISIS) Looks Forward To Licensing Anti-Clotting Drug To Bayer - Wall Street PR","isPartOf":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#website"},"primaryImageOfPage":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/isis-pharmaceuticals-inc-nasdaqisis-looks-forward-to-licensing-anti-clotting-drug-to-bayer-35647#primaryimage"},"image":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/isis-pharmaceuticals-inc-nasdaqisis-looks-forward-to-licensing-anti-clotting-drug-to-bayer-35647#primaryimage"},"thumbnailUrl":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/09\/Achillion-Pharmaceuticals-Inc.1.jpg","datePublished":"2015-05-05T12:49:50+00:00","breadcrumb":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/isis-pharmaceuticals-inc-nasdaqisis-looks-forward-to-licensing-anti-clotting-drug-to-bayer-35647#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/cablemanpro.com\/wallstreetpr\/isis-pharmaceuticals-inc-nasdaqisis-looks-forward-to-licensing-anti-clotting-drug-to-bayer-35647"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/isis-pharmaceuticals-inc-nasdaqisis-looks-forward-to-licensing-anti-clotting-drug-to-bayer-35647#primaryimage","url":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/09\/Achillion-Pharmaceuticals-Inc.1.jpg","contentUrl":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/09\/Achillion-Pharmaceuticals-Inc.1.jpg","width":259,"height":194},{"@type":"BreadcrumbList","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/isis-pharmaceuticals-inc-nasdaqisis-looks-forward-to-licensing-anti-clotting-drug-to-bayer-35647#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/cablemanpro.com\/wallstreetpr\/"},{"@type":"ListItem","position":2,"name":"ISIS Pharmaceuticals, Inc. (NASDAQ:ISIS) Looks Forward To Licensing Anti-Clotting Drug To Bayer"}]},{"@type":"WebSite","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#website","url":"https:\/\/cablemanpro.com\/wallstreetpr\/","name":"Wall Street PR","description":"Latest News From WallStreet","publisher":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/cablemanpro.com\/wallstreetpr\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#organization","name":"Wall Street PR","url":"https:\/\/cablemanpro.com\/wallstreetpr\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/logo\/image\/","url":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2019\/10\/brand-logo.png","contentUrl":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2019\/10\/brand-logo.png","width":537,"height":70,"caption":"Wall Street PR"},"image":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/WallStreetPR\/","https:\/\/x.com\/WallstreetPRs"]},{"@type":"Person","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/60ece280249b1fa366ae54f87bb8ae84","name":"Donna Fago","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/image\/","url":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2019\/06\/f15db860f556e28a86f628554c98485b.jpeg","contentUrl":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2019\/06\/f15db860f556e28a86f628554c98485b.jpeg","caption":"Donna Fago"},"description":"I believe in writing content Informing investors with the knowledge they need to invest better today- I have been following the markets for many years and was asked to join the team at WallStreetPR.com recently due to my passion for the markets.","sameAs":["http:\/\/www.WallStreetPR.com"],"url":"https:\/\/cablemanpro.com\/wallstreetpr\/author\/darcie-fago"}]}},"_links":{"self":[{"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/posts\/35647","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/comments?post=35647"}],"version-history":[{"count":0,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/posts\/35647\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/media\/32293"}],"wp:attachment":[{"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/media?parent=35647"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/categories?post=35647"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/tags?post=35647"},{"taxonomy":"stock_ticker","embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/stock_ticker?post=35647"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}